Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140855 · ClinicalTrials.gov registry record · Phase 2
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
A Phase 2 study, sponsored by Ludwig Institute for Cancer Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00140855: Clinical Trial Phase 2 study, sponsored by Ludwig Institute for Cancer Research.
NCT00140855 is a Phase 2 study that was terminated before completion, run by Ludwig Institute for Cancer Research. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00140855, a Phase 2 study, was terminated before completion, sponsored by Ludwig Institute for Cancer Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.
Primary Outcome
Computed tomography (CT) scans were performed at screening, and week 10. Response was assessed using RECIST version 1.0 (Therasse P et al. J Natl Cancer Inst 92:205-216). Per RECIST, target lesions are categorized as follows: complete response (CR): disappearance of all target lesions (no evaluable disease); partial response (PR): ≥ 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD): ≥ 20% increase in the sum of the longest diameter of target lesions; sta
Interventions
- BIOLOGICAL ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-06-08 |
| Est. Completion | 2007-07-01 |
| Phase | Phase 2 |
Why NCT00140855 stopped before completion
NCT00140855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which ipilimumab is the first listed.
NCT00140855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00140855 about?
NCT00140855 is a clinical study titled "A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma". The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.
What is the current status of trial NCT00140855?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2005-06-08. Estimated completion is 2007-07-01.
What interventions are being tested in trial NCT00140855?
The interventions under investigation include: ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00140855?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00140855's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI